- MASLD prevalence was 54.6% among chronic schizophrenia inpatients with prolonged hospitalisation.
- MASLD prevalence shows a gradient across obesity metabolic phenotypes, from MHNO to MUO.
- In MHNO group, antipsychotic polypharmacy and higher TyG-BMI independently associate with MASLD (OR 2.656 and 1.043).
Int J Gen Med. 2026 Aug 28;19:620778. doi: 10.2147/IJGM.S620778. eCollection 2026.
ABSTRACT
BACKGROUND: Chronic schizophrenia patients often present with exacerbated clinical symptoms and higher rates of fatty liver disease. This study is designed to compare the occurrence rates of metabolic dysfunction-associated steatotic liver disease (MASLD) and associated factors among hospitalized chronic schizophrenia patients with different obesity metabolic phenotypes.
METHODS: In this cross-sectional study, we retrospectively analyzed a cohort of 302 chronic schizophrenia patients aged 18-70 years. Patients were classified according to their obesity status (defined as body mass index ≥28 kg/m2) and metabolic health profile, resulting in four distinct obesity metabolic phenotypes: metabolically healthy non-obese (MHNO), metabolically unhealthy non-obese (MUNO), metabolically healthy obese (MHO), and metabolically unhealthy obese (MUO). Their sociodemographic information, biochemical and lipid parameters were retrospectively collected.
RESULTS: In this study, we found that the occurrence rate of metabolic dysfunction-associated steatotic liver disease (MASLD) among chronic schizophrenia patients with prolonged hospitalization was 54.6%. Within the MHNO grouping, MASLD-positive and MASLD-negative subgroups showed significant differences in key metabolic indicators, diabetes status, antipsychotic polypharmacy, and triglyceride-glucose-body mass index (TyG-BMI). Logistic regression analysis demonstrated that Antipsychotic polypharmacy (OR=2.656, P=0.007, 95% CI=1.299-5.429) and TyG-BMI (OR = 1.043, P <0.001, 95% CI = 1.029-1.057) were independently associated with MASLD in the MHNO group.
CONCLUSION: Metabolic dysfunction-associated steatotic liver disease is prevalent among chronic schizophrenia patients, with a notable prevalence gradient across obesity metabolic phenotypes. For metabolically healthy non-obese chronic schizophrenia patients, the importance of regular metabolic dysfunction-associated steatotic liver disease screening cannot be overlook ed.
PMID:42683120 | PMC:PMC13532882 | DOI:10.2147/IJGM.S620778
Share Evidence Blueprint
Save to Google Notes
Search Google Scholar
Save as PDF
⭐ My Revision List
